Affiliation:
1. Research Institute for Complex Issues of Cardiovascular Diseases
2. Novokuznetsk State Institute for Further Training of Physicians – branch of the Russian Medical Academy of Continuous Professional Education
Abstract
Introduction. A special position among the structural changes of the heart is occupied by left ventricular myocardial hypertrophy (LVH), which refers to the subclinical signs of heart damage in arterial hypertension (AH). Currently, the role of not only demographic, neuroendocrine, but also genetic factors in the development and progression of LVH is no longer in doubt.Aim. To assess the role of clinical and genetic factors in the progression of LVH in patients with hypertension based on the results of a dynamic 5-year follow-up of a cohort of Shors.Materials and methods. The survey of the indigenous population in Gornaya Shoria was carried out in two time periods: onetime (from 2013 to 2017) and prospective (from 2018 to 2020). The study included the adult population (18 years and older) – a total of 901 people – by continuous method. A group of patients with hypertension was identified – 367 people (40.7%). LVH was assessed by electrocardiography and/or echocardiography. The prospective stage of the study included patients with hypertension who had not previously received antihypertensive therapy (263 people). The control and correction of blood pressure numbers was carried out annually, the dynamics of LVH was assessed after five years.Results. Clinical predictors of negative dynamics of LVH were established: obesity (OR = 3.61), abdominal obesity (OR = 4.11), impaired carbohydrate metabolism (OR = 2.83), low high-density lipoprotein cholesterol (OR = 2.05). Genetic markers also demonstrated their involvement in the progression of LVH: allele D of the ACE gene, allele C of the AGTR1 gene, and 4a of the eNOS gene (OR = 9.69; OR = 6.72; OR = 6.37, respectively).Conclusion. The associations of clinical and genetic factors with LVH identified in the Shor cohort can be considered as predictors of myocardial remodeling in hypertension. The data obtained support the hypothesis that polymorphisms of the renin-angiotensin-aldosterone system and endothelial function can influence the phenotype, creating new approaches to the possible prediction of unfavorable outcomes.
Reference24 articles.
1. Medvedev N.V., Gorshunova N.K. Correlation between variants of left ventricular myocardial remodeling and its interstitial fibrosis in assessing the prognosis of elderly patients with arterial hypertension. Clinical Gerontology. 2017;(9-10):43–44. (In Russ.) Available at: https://kg.newdiamed.ru/issue/id39227/id40403.
2. Lazutkina A.Yu., Gorbunov V.V. Risk factors and progression of left ventricular myocardial hypertrophy. Saratov Journal of Medical Scientific Research. 2015;11(2):141–145. (In Russ.) Available at: https://ssmj.ru/2015/2/141.
3. Ozhereleva M.V., Ovchinnikov A.G. Special aspects of remodeling of the left ventricle in hypertensive disease. Medical Herald of the South of Russia. 2017;8(4):14–22. (In Russ.) https://doi.org/10.21886/2219-8075-2017-8-4-14-22.
4. Shavarova E.K., Kobalava Z.D., Ezhova N.E., Khomova I.A., Bazdyreva E.I. Early structural and functional left ventricular disorders in young patients with hypertension: a role of insulin resistance. Russian Journal of Cardiology. 2020;25(3):3774. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3774.
5. Smirnova M.D., Fofanova T.V., Khasanova Z.B., Ovchinnikov A.G., Ageev F.T., Postnov A.Yu. Associations between clinical course, left ventricular hypertrophy severity and ACE gene I/D polymorphism in patients with hypertrophic cardiomyopathy and hypertensive heart. Russian Journal of Cardiology. 2009;(2):65–69. (In Russ.) Available at: https://russjcardiol.elpub.ru/jour/article/1340/1065.